Loading
A phase 2/3 trial of Netupitant and palonosetron and Dexamethasone in Cervical cancer, run by Christina Ruhlmann, with a status the registry has not verified recently.
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin is a phase 2/3 interventional study registered as NCT03668639 by Christina Ruhlmann, with 80 participants planned, started 2018-09-05 and due to reach its primary completion in 2023-03-01. Interventions recorded: Akynzeo, Dexamethasone. Conditions recorded: Chemotherapy-induced Nausea and Vomiting, Adverse Event, Cervical Cancer.
Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Cervical cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Netupitant and palonosetron, Dexamethasone and the tag pipeline.
Shares Netupitant and palonosetron and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Cervical cancer and the tag pipeline.
Shares Dexamethasone and the tag pipeline.
Shares Dexamethasone and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/